348 related articles for article (PubMed ID: 24919955)
21. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
23. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.
Onda M; Matsuda S; Higaki S; Iijima T; Fukushima J; Yokokura A; Kojima T; Horiuchi H; Kurokawa T; Yamamoto T
Cancer; 1996 Jan; 77(1):71-8. PubMed ID: 8630943
[TBL] [Abstract][Full Text] [Related]
24. [Multivariate analysis for prognostic factors among 43 patients with osteosarcoma].
Zhang B; Pang QJ; Zhang HJ; Yuan Y
Zhongguo Gu Shang; 2011 Dec; 24(12):982-6. PubMed ID: 22276503
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
26. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma.
Sun K; Gong C; Peng H; Fang H; Zhou J; Li J; Chen S; Zheng H
Mol Med Rep; 2017 Nov; 16(5):6953-6957. PubMed ID: 28901496
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract][Full Text] [Related]
28. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma.
Tian ZZ; Guo XJ; Zhao YM; Fang Y
Int J Clin Exp Pathol; 2015; 8(11):15138-42. PubMed ID: 26823857
[TBL] [Abstract][Full Text] [Related]
30. [Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity].
Chen Y; Wang CM; Shi YQ; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):899-904. PubMed ID: 23336375
[TBL] [Abstract][Full Text] [Related]
31. Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma.
Feng H; Guo P; Wang J; Xu J; Xie C; Gao F
Pathol Res Pract; 2016 Apr; 212(4):319-24. PubMed ID: 26936024
[TBL] [Abstract][Full Text] [Related]
32. Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma.
Li W; He X; Xue R; Zhang Y; Zhang X; Lu J; Zhang Z; Xue L
Pathol Res Pract; 2016 Oct; 212(10):861-866. PubMed ID: 27623205
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.
Shi K; Wang SL; Shen B; Yu FQ; Weng DF; Lin JH
World J Surg Oncol; 2019 Jan; 17(1):23. PubMed ID: 30691475
[TBL] [Abstract][Full Text] [Related]
34. The expression of CRM1 is associated with prognosis in human osteosarcoma.
Yao Y; Dong Y; Lin F; Zhao H; Shen Z; Chen P; Sun YJ; Tang LN; Zheng SE
Oncol Rep; 2009 Jan; 21(1):229-35. PubMed ID: 19082467
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma.
Taheriazam A; Bahador R; Karbasy SH; Jamshidi SM; Torkaman A; Yahaghi E; Shakeri M
Diagn Pathol; 2015 Sep; 10():166. PubMed ID: 26377680
[TBL] [Abstract][Full Text] [Related]
36. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
37. Improved survival in osteosarcoma patients with atypical low vascularization.
Kunz P; Fellenberg J; Moskovszky L; Sápi Z; Krenacs T; Machado I; Poeschl J; Lehner B; Szendrõi M; Ruef P; Bohlmann M; Bosch AL; Ewerbeck V; Kinscherf R; Fritzsching B
Ann Surg Oncol; 2015 Feb; 22(2):489-96. PubMed ID: 25155396
[TBL] [Abstract][Full Text] [Related]
38. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations.
Cho WH; Song WS; Jeon DG; Kong CB; Kim MS; Lee JA; Yoo JY; Kim JD; Lee SY
Ann Surg Oncol; 2010 Mar; 17(3):702-8. PubMed ID: 19921336
[TBL] [Abstract][Full Text] [Related]
39. Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma.
Wu PF; Dai ZT; Liu WD; Zhao ZX; Kong YH
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1428-1433. PubMed ID: 30840263
[TBL] [Abstract][Full Text] [Related]
40. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
